The 30th National High School Manga Championship (Manga Koshien)
19.7.2021 08:30:00 EEST | Business Wire | Press release
Manga Koshien is a competition where high school students compete for the position of Number 1 by creating one-page manga since 1992.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210718005034/en/
poster (Graphic: Business Wire)
About 300 high school teams, comprising three to five students each, enter every year. Of these, 30 teams are selected to go on to the championship round in August. Competing teams battle it out with their ideas, techniques and teamwork, all within a limited amount of time.
Talented students participating in the main round may also be scouted by major manga publishers and perhaps even debut as professionals!
[ The 30th Manga Koshien ]
As this year’s tournament is celebrating the 30th anniversary of our event, we will advance a total of 40 teams, 10 more than usual, to the final.
There are various events by professional manga artists between the competitions, and it will be a spectacular delivery. Please take a look.
- Semifinal round: August 6th (Fri)
- The final round: August 7th (Sat)
- URL: https://mangaoukoku-tosa.jp/manga-koshien30
[ Manga Koshien Gokko ]
An online contest for high school individual students or teams from all over the world who could not participate in the Manga Koshien Finals.
- Work theme: “30” (Free theme as long as “30” is related to the content or visual elements)
- Eligibility for submission: Students whose school level is equivalent to that of high schools in Japan.
- Judging: Submitted works will be displayed on a public website and subject to general voting.
The number of votes cast in the general vote determines the results from 1st to 3rd place.
-
Supplementary prize:
1st place: Wacom Cintiq 16, CLIP STUDIO PAINT EX 2 (Device Plan 2 Year Edition), Sleeping Cat plush toy (big size)
2nd place: CLIP STUDIO PAINT PRO (2 device plan, 2 year subscription), Sleeping Cat plush toy (middle size)
3rd place: CLIP STUDIO TABMATE, Sleeping Cat plush toy (small size)
- Submission period: July 17th (Sat) 0:00 to August 6th (Fri) 16:00 (JST)
- Voting period: July 17th (Sat) 0:00 to August 7th (Sat) 15:00 (JST)
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210718005034/en/
Contact information
For Enquiries
Manga Kingdom Tosa Promotion Division, Department of Culture, Community, and Sports, Kochi Prefecture
Email: 141701@ken.pref.kochi.lg.jp
Manga Kingdom Tosa Promotional Committee
Enquiries Regarding this press release
In-Charge: Yasuaki Okamatsu and Maya Nakahira
Manga Kingdom Tosa Promotion Division, Department of Culture, Community, and Sports, Kochi Prefecture
Tel: +81-88-823-9711
Fax: +81-88-823-9296
Email: 141701@ken.pref.kochi.lg.jp
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom